Static list review - October 2016

Decision to remain on the static guidance list

Gemcitabine for the treatment of metastatic breast cancer was added to the static list in May 2010.

Guidance is moved to the static list following consultation with consultees and commentators when it is clear that there is no new research available that would have any material effect on the current guidance. Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

We have concluded that there has been no change in the evidence base that is likely to lead to a change in the existing recommendations.

As a result, we have decided that TA116 should remain on the static list and no further action is required at this time.

Static list review paper


This page was last updated: 18 October 2016